Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report) CEO Todd Harris sold 5,698 shares of the company’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $24.31, for a total value of $138,518.38. Following the completion of the transaction, the chief executive officer now directly owns 1,496,729 shares in the company, valued at approximately $36,385,481.99. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Tyra Biosciences Stock Performance
Shares of TYRA opened at $24.36 on Monday. The company’s 50-day simple moving average is $21.29 and its 200-day simple moving average is $18.72. Tyra Biosciences, Inc. has a 1 year low of $10.38 and a 1 year high of $25.14. The stock has a market capitalization of $1.28 billion, a PE ratio of -14.50 and a beta of 1.01.
Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. On average, sell-side analysts predict that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current year.
Analyst Upgrades and Downgrades
Read Our Latest Stock Analysis on TYRA
Institutional Investors Weigh In On Tyra Biosciences
A number of large investors have recently modified their holdings of the company. RA Capital Management L.P. grew its stake in shares of Tyra Biosciences by 43.9% during the first quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock worth $170,832,000 after purchasing an additional 3,180,155 shares in the last quarter. BVF Inc. IL lifted its stake in Tyra Biosciences by 70.1% during the first quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock worth $76,444,000 after purchasing an additional 1,921,599 shares during the last quarter. Kynam Capital Management LP acquired a new position in Tyra Biosciences in the fourth quarter valued at approximately $4,712,000. Perceptive Advisors LLC increased its stake in Tyra Biosciences by 50.5% in the second quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after purchasing an additional 338,208 shares during the last quarter. Finally, Ally Bridge Group NY LLC acquired a new position in shares of Tyra Biosciences in the 2nd quarter valued at $4,232,000. 84.14% of the stock is owned by hedge funds and other institutional investors.
Tyra Biosciences Company Profile
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Recommended Stories
- Five stocks we like better than Tyra Biosciences
- How to Use the MarketBeat Dividend Calculator
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- There Are Different Types of Stock To Invest In
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Consumer Staples Stocks, Explained
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.